Skip Navigation



Annals of Oncology Advance Access published online on November 2, 2009
Annals of Oncology, doi:10.1093/annonc/mdp490
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ennishi, D.
Right arrow Articles by Tanimoto, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ennishi, D.
Right arrow Articles by Tanimoto, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

D. Ennishi1,2, H. Asai2, Y. Maeda1, K. Shinagawa1, K. Ikeda1, M. Yokoyama2, Y. Terui2, K. Takeuchi3, T. Yoshino4, K. Matsuo5, K. Hatake2 and M. Tanimoto1,*

1 Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama
2 Department of Medical Oncology and Hematology, Cancer Institute Hospital, Tokyo
3 Division of Pathology, The Japanese Foundation for Cancer Research, Tokyo
4 Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
5 Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

* Correspondence to: Dr M. Tanimoto, Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Okayama city, Okayama 700-8558, Japan. Tel: +81-86-235-7227; Fax: +81-86-232-8226; E-mail: tanimoto{at}md.okayama-u.acjp

Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear.

Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins.

Results: The 3-year progression-free survival rates were 84% and 73% (P = 0.38), while the overall survival rates were 89% and 78% (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis.

Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.

diffuse large B-cell lymphoma, rituximab, statin

Received for publication July 6, 2009. Revision received September 9, 2009. Accepted for publication September 10, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.